Literature DB >> 12633663

The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis.

Thomas Blankenstein1, Zhihai Qin.   

Abstract

IFN-gamma contributes to the rejection of transplantable tumors and the inhibition of methylcholanthrene (MCA)-induced carcinogenesis by different mechanisms. In most tumor transplantation models, tumor rejection requires IFN-gamma receptor expression by host cells, but not by tumor cells. IFN-gamma produced by either CD4+ or CD8+ T cells acts on non-hematopoietic tumor stroma cells and, either directly or indirectly, induces angiostasis. This prevents rapid tumor burden and allows residual tumor cells to be eliminated. In some models, IFN-gamma also contributes to the destruction of existing tumor blood vessels. During MCA-induced tumorigenesis IFN-gamma is involved in the inhibition of MCA diffusion by encapsulation and reduction of DNA damage. This mechanism may primarily protect tissue from damage and simultaneously inhibit tumor development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12633663     DOI: 10.1016/s0952-7915(03)00007-4

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  28 in total

1.  Prostaglandin E2 Reverses the Effects of DNA Methyltransferase Inhibitor and TGFB1 on the Conversion of Naive T Cells to iTregs.

Authors:  Mehmet Sahin; Emel Sahin
Journal:  Transfus Med Hemother       Date:  2019-09-19       Impact factor: 3.747

2.  Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts.

Authors:  Hiroyoshi Nishikawa; Takuma Kato; Isao Tawara; Tetsushi Takemitsu; Kanako Saito; Linan Wang; Yoshinori Ikarashi; Hiro Wakasugi; Toshinori Nakayama; Masaru Taniguchi; Kagemasa Kuribayashi; Lloyd J Old; Hiroshi Shiku
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-16       Impact factor: 11.205

3.  A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy.

Authors:  Hyun-Il Cho; Eduardo Reyes-Vargas; Julio C Delgado; Esteban Celis
Journal:  Cancer Res       Date:  2012-02-24       Impact factor: 12.701

4.  Optimization of soluble human interferon-γ production in Escherichia coli using SUMO fusion partner.

Authors:  Fenfen Zhu; Qi Wang; Hefang Pu; Shasha Gu; Lan Luo; Zhimin Yin
Journal:  World J Microbiol Biotechnol       Date:  2012-10-06       Impact factor: 3.312

5.  CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.

Authors:  Chrysoula I Liakou; Ashish Kamat; Derek Ng Tang; Hong Chen; Jingjing Sun; Patricia Troncoso; Christopher Logothetis; Padmanee Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-25       Impact factor: 11.205

Review 6.  Intravital imaging of CD8+ T cell function in cancer.

Authors:  Thorsten R Mempel; Christian A Bauer
Journal:  Clin Exp Metastasis       Date:  2008-07-30       Impact factor: 5.150

7.  Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects.

Authors:  Hyun-Il Cho; Esteban Celis
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

Review 8.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486

9.  Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo.

Authors:  Tihui Fu; Kui Shin Voo; Rong-Fu Wang
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.

Authors:  Amorette Barber; Charles L Sentman
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.